FDA approves new painkiller designed to avoid opioid addiction risk
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
FDA Opens Up A New Path To The U.S. Market For This Under 30 Biotech Startup
More than 10 million babies have been born through IVF, yet the process is still invasive and costly. Plus, why a venture ...
Gameto launches Phase III iPSC fertility trial following IND greenlight
The company claims its Fertilo system can mature eggs outside the body using 80% fewer hormonal injections than typical ...
Biotech Stocks Facing FDA Decision In February 2025
February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...
FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
Eagle-Tribune1d
Gameto Announces FDA IND Clearance for Fertilo, the First iPSC-Based Therapy to Enter U.S. Phase 3 Clinical Trials
Gameto, a clinical-stage biotech company developing iPSC-based therapies for women’s health, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug ...
precisionmedicineonline1d
Atalanta Therapeutics Raises $97M in Series B Financing to Advance RNAi Therapies for CNS Diseases
Atalanta aims to create disease-modifying therapies by silencing certain genes in the central nervous system, including in the brain and spinal cord.
TMCnet2d
Vyluma Announces Acceptance of Drug Application for NVK002 by China's National Medical Products Administration (NMPA)
With its acceptance by the NMPA, NVK002 is now under regulatory review across three major global markets: the United States, the European Union, and China. This milestone reinforces Vyluma’s vision of ...